Cataract Therapeutics

The planned phase 3 trial will evaluate the triamcinolone acetonide injectable for managing inflammation and pain after cataract surgery.

A phase IV study in China found that 22 of 26 patients achieved complete healing of a persistent corneal epithelial defect or corneal ulcer after 8 weeks.

The acquisition focuses on LayerBio's OcuRing-K technology, with plans to initiate the next clinical trial.

Ophthalmologists discuss the most impactful advancements reshaping patient care over five decades.

In honor of Ophthalmology Times’ 50th anniversary, anterior segment surgeons attending ASCRS 2025 weigh in on the innovations that defined modern ophthalmology.

From Nobel laureates to AI-driven research, the Wilmer Eye Institute honors a century of transforming vision science and care.

The center aims to optimize patients' vision with a range of cataract and corneal refractive procedures and minimize reliance on glasses and contacts.

FDA noted that the US phase 2 trial may serve as 1 of the 2 pivotal trials required for NDA filing.

Tenpoint Therapeutics and Visus Therapeutics have merged to focus on aging-related ocular conditions, with key products including BRIMOCHOL PF for presbyopia and therapies for cataracts and geographic atrophy.

According to the company, VVN461, a non-steroidal dual JAK1/TYK2 immunomodulator, achieved its primary endpoint, demonstrating statistical and clinical efficacy compared to vehicle in treating post-operative inflammation following cataract surgery.

Melt Pharmaceuticals announced positive results from its Phase 3 study of MELT-300, a non-IV, non-opioid tablet for procedural sedation during cataract surgery. The results support a regulatory submission, with potential to revolutionize sedation practices in various medical specialties.

The EnVision Summit, co-founded by Bonnie An Henderson, MD, is a unique family-oriented, multispecialty ophthalmology CME conference, along with a newly introduced optometry track. Henderson sits down with Ophthalmology Times to talk about the 2025 conference that will take place February 14 to 17 at the Caribe Hilton San Juan, in Puerto Rico.

The phase 3 trial was conducted by licensee, Grand Pharma in Chinese cataract surgery patients.

According to the company, there are no FDA-approved pharmacological therapies for age-related cataracts. Its C-KAD eye drop, improves vision in patients with early-to-moderate cataracts, by penetrating the eye to reduce lens clouding, the main cause for cataracts.

MELT-300, a non-IV, non-opioid tablet for procedural sedation during cataract surgery.

The drop improves vision by breaking up degraded protein complexes that cause lens clouding

MELT-300 is a non IV, non-opioid tablet that combines fixed doses of midazolam (3mg) and ketamine (50mg).

Abbreviated New Drug Applications seek potential approval of a generic drug product.

Physicians should consider the roles of verbal and ocular anesthesia.

The angled bow-tie pattern of astigmatism was corrected more accurately compared with the asymmetric bow-tie pattern of astigmatism

A singular celebration of science over the decades

Despite recognition of lenticular glutathione’s importance in lens formation for decades, why it declines with age remains a mystery.

Alice Epitropoulos, MD, discusses the importance of considering ocular surface health in cataract surgery patients.

An expert discusses how to ensure optimal administration.

According to the company, in a clinical trial of chloroprocaine hydrochloride ophthalmic gel in patients undergoing routine cataract surgery, patients treated with the gel did not require any supplemental treatment to complete the intended surgical procedure.